Caxton Associates LP purchased a new position in Becton, Dickinson and Company (NYSE:BDX) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 3,400 shares of the medical instruments supplier’s stock, valued at approximately $624,000.

Other institutional investors have also added to or reduced their stakes in the company. Crestwood Advisors Group LLC acquired a new position in Becton, Dickinson and during the first quarter worth $101,000. North Star Investment Management Corp. boosted its position in Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 18 shares in the last quarter. Parkside Financial Bank & Trust boosted its position in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares in the last quarter. Financial Architects Inc boosted its position in shares of Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 261 shares during the period. Finally, QCI Asset Management Inc. NY boosted its position in shares of Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after buying an additional 60 shares during the period. Institutional investors and hedge funds own 75.71% of the company’s stock.

Becton, Dickinson and Company (NYSE:BDX) traded up 1.08% on Friday, hitting $200.36. The stock had a trading volume of 1,251,199 shares. The company has a market cap of $45.59 billion, a price-to-earnings ratio of 58.02 and a beta of 1.05. The company’s 50 day moving average price is $198.90 and its 200-day moving average price is $187.70. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. Becton, Dickinson and’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.35 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be given a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.46%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s payout ratio is 83.43%.

TRADEMARK VIOLATION WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/caxton-associates-lp-purchases-new-stake-in-becton-dickinson-and-company-nysebdx/1479340.html.

A number of equities analysts recently commented on BDX shares. BidaskClub cut Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Bank of America Corporation reiterated a “buy” rating and issued a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a research note on Monday, July 17th. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday. One research analyst has rated the stock with a sell rating, six have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $195.79.

In related news, VP Jeffrey S. Sherman sold 28,765 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total value of $5,349,714.70. Following the sale, the vice president now directly owns 70,821 shares in the company, valued at approximately $13,171,289.58. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the sale, the insider now owns 26,638 shares in the company, valued at $5,279,917.98. The disclosure for this sale can be found here. Insiders have sold a total of 44,019 shares of company stock worth $8,368,433 over the last quarter. Insiders own 1.40% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.